Malignant Female Reproductive System Neoplasm

Malignant Female Reproductive System Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

6,252 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,462
Recruiting: 819
Ph III recruiting: 96
Growth YoY: +6%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 28.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (740)

clinicaltrialsPublishedShowing 51–100 of 6,252 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04044859	ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)	active not recruiting	Phase 1	120	USWM CT, LLCINDUSTRY	3	Sep 23, 2026	clinicaltrials
NCT04145518	Mechanistic Characterization of Uterine Pain(MCUP)	completed	Phase 4	183	Endeavor HealthOTHER	1	Sep 23, 2026	clinicaltrials